2025 Article # 5
July 2025 Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment August 2018 • Volume 22, number 4, pages 407 - 414 • DOI: 10.1188/18.CJON.407-414 Carissa Laudati, Caroline Clark, Andrea Knezevic, Zhigang Zhang, and Margaret Barton-Burke Background: Strategies to reduce hypersensitivity reaction (HSR) incidence with rituximab include premedications and slow titration. Literature is lacking on the priming method used when preparing rituximab IV lines and the potential impact on HSR incidence. Objectives: The primary objective is to evaluate HSR incidence in titrated first-dose rituximab infusions when priming IV lines with rituximab, as compared to priming with diluent. Methods: A retrospective, comparative, descriptive study with two arms (rituximab- versus diluent-primed) was conducted. Variables were HSR incidence in relation to priming method, age, sex, diagnosis, a...